BIOPHARMA
ByWill Merck’s $9.2 Billion Acquisition of Cidara Therapeutics Reshape the Future of Long-Acting Influenza Prevention?
Rahway, NJ & San Diego, CA | January 2026 Merck & Co., Inc. has confirmed that its approximately…
Can Insilico Medicine’s Hong Kong IPO Signal a Turning Point for AI-Driven Drug Discovery in Global Capital Markets?
Hong Kong | January 4, 2026 Insilico Medicine, a China-based, AI-driven drug discovery company backed by Qiming Venture…
Did NVIDIA Become the Central AI Catalyst for Biopharma in 2025—And Which Players Benefited Most?
2025 marked a pivotal year for artificial intelligence in biopharma. As life sciences companies moved beyond isolated AI…
Which AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
Does the U.S. Exit from WHO Redefine Global Health Governance? Washington Completes Historic Withdrawal
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal
January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics, a…
